艾司西酞普兰片治疗抑郁症的Ⅱ期临床研究  

The second phase clinical trial of escitalopram for the treatment of the major depressive disorder

作　　者：王继才[1] 欧阳虹[1] 李文昱[1] 许秀峰[1] 

机构地区：[1]昆明医学院第一附属医院精神科,昆明650032

出　　处：《精神医学杂志》2008年第5期330-333,共4页Journal of Psychiatry

摘　　要：目的评价艾司西酞普兰片治疗抑郁症的有效性和安全性。方法对符合《DSM-Ⅳ》抑郁症诊断标准的36例抑郁症患者进行艾司西酞普兰片和西酞普兰的对照研究,其中艾司西酞普兰片组18例(10mg/d),西酞普兰组18例(20mg/d),共治疗6周。采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床总体评定量表(CGI)评定临床疗效,不良事件量表(AE)评定安全性。结果经6周治疗后,艾司西酞普兰组治疗总有效率为88.9%,西酞普兰组为75.0%,两组比较差异无显著性(P>0.05)。两组HAMD、HAMA评分治疗前后差异有高度显著性(P<0.001)。两组药物不良反应的发生率无显著性差异(P>0.05),常见的不良反应有恶心、口干、头昏等。结论艾司西酞普兰片治疗抑郁症疗效好,不良反应少而轻,适合临床应用。Objective To determine the efficacy and safety of escitalopram for treating the depressive patients. Methods A controlled study was carried out between 36 patients who met the DSM-Ⅳ criteria of major depression and depressed episode. There were 18 patients with escitalopram（10mg/d）and the others with citalopram （20mg/d）for 6 weeks. The efficacy was assessed by Hamilton Depression Rating Scale（HAMD）, Hamilton Anxiety Scale（HAMA）, Clinical Global Impression （CGI） and the safety was assessed by Adverse Event Scale. Results After six weeks treatment, the improvement rate of escitalopram group and eitalopram group were 88.9% and 75.0% ,respectively,and there was no significantly different between two groups （P〉0.05）. The scores of HAMD and HAMA in two groups were significant difference before and after treatment（P〈0. 001）. The main adverse events of two groups had nausea, dry mouth, dizziness, et al. There had no significant difference in incidence of adverse events between two groups（P〉0.05）. Conclusion Escitalopram is an effective antidepressant with fewer side effects, better safety and suiting for clinical use.

关 键 词：抑郁症 艾司西酞普兰 西酞普兰 安全性 

分 类 号：R749.4[医药卫生—神经病学与精神病学]